Jean Charles Soria

Jean Charles Soria

UNVERIFIED PROFILE

Are you Jean Charles Soria?   Register this Author

Register author
Jean Charles Soria

Jean Charles Soria

Publications by authors named "Jean Charles Soria"

Are you Jean Charles Soria?   Register this Author

100Publications

4604Reads

48Profile Views

Optimizing oncolytic virotherapy in cancer treatment.

Nat Rev Drug Discov 2019 Sep 10;18(9):689-706. Epub 2019 Jul 10.

Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41573-019-0029-0DOI Listing
September 2019

Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA.

Cancer Immunol Res 2019 Jul 4;7(7):1120-1134. Epub 2019 Jun 4.

The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-19-0023DOI Listing
July 2019

Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.

Clin Cancer Res 2019 May 14;25(9):2691-2698. Epub 2019 Jan 14.

Research & Development, MedImmune, Gaithersburg, Maryland.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-3904DOI Listing
May 2019

[New treatments in immuno-oncology: a revolution and a formidable scientific and clinical challenge].

Med Sci (Paris) 2017 Jun-Jul;33(6-7):563-564. Epub 2017 Jul 19.

Département d'innovation thérapeutique et d'essais précoces (DITEP Gustave-Roussy, université Paris Saclay Villejuif, France ; Inserm, U981, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1051/medsci/20173306001DOI Listing
April 2019

The "Guardian of the Genome"-An Old Key to Unlock the ERCC1 Issue.

Clin Cancer Res 2019 Apr 6;25(8):2369-2371. Epub 2019 Feb 6.

INSERM U981, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-4123DOI Listing
April 2019

Beyond DNA repair: the novel immunological potential of PARP inhibitors.

Mol Cell Oncol 2019 13;6(2):1585170. Epub 2019 Mar 13.

Faculté de médicine, Université Paris Saclay, Université Paris-Sud, Le Kremlin Bicêtre, France.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/23723556.2019.1
Publisher Site
http://dx.doi.org/10.1080/23723556.2019.1585170DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512907PMC
March 2019

Moving from academia to industry in the field of oncology.

Clin Adv Hematol Oncol 2019 Jan;17(1):38-39

MedImmune, Gaithersburg, Maryland.

View Article

Download full-text PDF

Source
January 2019

Hyperprogressive disease: recognizing a novel pattern to improve patient management.

Nat Rev Clin Oncol 2018 12;15(12):748-762

Département d'Innovation Thérapeutique et des Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0111-2
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0111-2DOI Listing
December 2018

Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?

Eur J Cancer 2018 11 14;103:108-119. Epub 2018 Sep 14.

Department of Interventional Radiology, Gustave Roussy, Villejuif, France; Faculté de Médecine, Kremlin-Bicêtre, Université Paris Sud, France; Laboratory of Translational Research in Immunology - LRTI, INSERM U1015, Gustave Roussy, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.08.003DOI Listing
November 2018

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.

Eur J Cancer 2018 11 1;104:1-8. Epub 2018 Oct 1.

Medical Oncology Division, START Madrid Centro Integral Oncológico Clara Campal, Calle de Oña, 10, 28050, Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.07.011DOI Listing
November 2018

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

J Clin Oncol 2018 10 7;36(30):3007-3014. Epub 2018 May 7.

Jeremy Lewin and Lillian L. Siu, Princess Margaret Cancer Center, Toronto, Ontario, Canada; Jean-Charles Soria and Christophe Massard, Institut Gustave Roussy and University Paris-Sud, Villejuif; Jean-Pierre Delord, Institut Claudius Regaud Oncopole, Toulouse; Mohamed Bekradda, Oncology Therapeutic Development, Clichy; Keyvan Rezai, Hôpital René Huguenin, Saint-Cloud, France; Anastasios Stathis, Oncology Institute of Southern Switzerland, Bellinzona; Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Ahmad Awada and Philippe G. Aftimos, Université Libre de Bruxelles, Brussels, Belgium; and Zhen Zeng, Azher Hussain, and Susan Perez, Merck & Co, Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.2292DOI Listing
October 2018

Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 10 14;36(30):2995-3006. Epub 2018 Aug 14.

Siddhartha Devarakonda, Irena Lanc, and Ramaswamy Govindan, Washington University School of Medicine; Siddhartha Devarakonda and Ramaswamy Govindan, Siteman Cancer Center; Robert Fulton, Washington University School of Medicine, St. Louis; Ashiq Masood, University of Missouri Kansas City, Kansas City, MO; Federico Rotolo, Ken A. Olaussen, Gwénaël Le Teuff, Jean-Pierre Pignon, and Stefan Michiels, Université Paris-Saclay; Federico Rotolo, Ken A. Olaussen, Gwénaël Le Teuff, Jean-Pierre Pignon, Jean-Charles Soria, and Stefan Michiels, Gustave Roussy Cancer Campus, Villejuif; Elisabeth Brambilla and Anne McLeer-Florin, Centre Hospitalier Universitaire de Grenoble, La Tronche, France; Ming-Sound Tsao, Shingo Sakashita, and Frances A. Shepherd, Princess Margaret Cancer Centre and University of Toronto, Toronto; Keyue Ding and Lesley Seymour, Queen's University Kingston, Ontario, Canada; Stephen L. Graziano, State University of New York Upstate Medical University, Syracuse, NY; Robert Kratzke, University of Minnesota Medical School, Minneapolis, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.1963DOI Listing
October 2018

Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer.

Am Soc Clin Oncol Educ Book 2017;37:12-17

From the Department of Oncology Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Department of Oncology Medicine, Hospital de la Vall d'Hebron, Barcelona, Spain; Institut National du Cancer, Boulogne-Billancourt, France; University Paris-Sud and Gustave Roussy Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_100007DOI Listing
September 2018

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

Lancet Oncol 2018 09 14;19(9):1180-1191. Epub 2018 Aug 14.

Gustave Roussy-CentraleSupélec-Therapanacea Centre of Artificial Intelligence in Radiation Therapy and Oncology, Gustave Roussy Cancer Campus, Villejuif, France; Radiomics Team, Molecular Radiotherapy INSERM U1030, Paris-Sud University, Gustave Roussy Cancer Campus, and University of Paris-Saclay, Villejuif, France; Department of Drug Development, Gustave Roussy Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30413-3DOI Listing
September 2018

Does smoking alter the mutation profile of human papillomavirus-driven head and neck cancers?

Eur J Cancer 2018 05 20;94:61-69. Epub 2018 Mar 20.

Department of Head and Neck Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, F-94805, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.02.013DOI Listing
May 2018

Multilayer global longitudinal strain in patients with cancer: A comparison of two vendors.

Arch Cardiovasc Dis 2018 Apr;111(4):285-296

Service de cardiologie, hôpital Saint-Antoine, AP-HP, université Pierre-et-Marie-Curie, Paris-Sorbonne, Paris VI, 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acvd.2017.11.003DOI Listing
April 2018

A novel antibody-based approach to detect the functional ERCC1-202 isoform.

DNA Repair (Amst) 2018 04 11;64:34-44. Epub 2018 Feb 11.

INSERM U981, Gustave Roussy, 94805, Villejuif, France; Faculté de médecine, Université Paris-Sud, 94270, Kremlin-Bicêtre, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dnarep.2018.02.002DOI Listing
April 2018

Are phase I trials safe for older patients?

J Geriatr Oncol 2018 03 8;9(2):87-92. Epub 2017 Sep 8.

Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif Cedex F-94805, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2017.08.012DOI Listing
March 2018

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

Eur J Cancer 2018 03 10;91:21-29. Epub 2018 Jan 10.

Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Service de Médecine Interne et Immunologie Clinique, F-94275, Le Kremlin-Bicêtre, France; INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases, F-94276, Le Kremlin-Bicêtre, France; Université Paris Sud, UMR 1184, F-94276, Le Kremlin-Bicêtre, France; CEA, DSV/iMETI, IDMIT, F-92265, Fontenay-aux-Roses, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.12.008DOI Listing
March 2018

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.

J Clin Oncol 2018 03 17;36(9):850-858. Epub 2018 Jan 17.

F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA; Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autònoma de Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London, London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.1644DOI Listing
March 2018

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Eur J Cancer 2018 03 3;92:1-10. Epub 2018 Feb 3.

Drug Development Department, Gustave Roussy, Department of Medical Oncology, Faculté de Medicine Paris-Sud XI, Kremlin-Bicêtre, France; Gustave Roussy Department of Medical Oncology, Faculté de Medicine Paris-Sud XI, Kremlin-Bicêtre, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.12.020DOI Listing
March 2018

Osimertinib in EGFR Mutation-Positive Advanced NSCLC.

N Engl J Med 2018 03;378(13):1262-1263

Emory University School of Medicine, Atlanta, GA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1801669DOI Listing
March 2018

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.

Br J Cancer 2018 02 16;118(3):344-352. Epub 2018 Jan 16.

Department of Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer-Oncopole, Toulouse 31100, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.436DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808039PMC
February 2018

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

J Clin Oncol 2018 01 26;36(1):7-13. Epub 2017 Oct 26.

Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for Pharmaceutical Sciences, Utrecht, the Netherlands; Jean Charles Soria, Institut Gustave Roussy, University of Paris-Sud, and University of Paris-Saclay, Villejuif, France; Patrick Y. Wen, Dana-Farber Cancer Institute, Boston, MA; Christoph Zielinski, Comprehensive Cancer Center, Medical University Vienna; Vienna, Austria; and Gladys Urbanowitz, Bijoyesh Mookerjee, Dazhe Wang, and Fatima Rangwala, Novartis Oncology, East Hanover, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.6785DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791845PMC
January 2018

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

N Engl J Med 2018 01 18;378(2):113-125. Epub 2017 Nov 18.

From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit, University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit, Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheong-ju (K.H.L.), the Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul (B.C.C.), and the Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.); National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J.E.G.); the Department of Oncology, University College London Hospitals Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all in the United Kingdom; and Emory University School of Medicine, Winship Cancer Institute, Atlanta (S.S.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1713137DOI Listing
January 2018

[Hodgkin lymphoma: Current and future therapeutic strategies].

Bull Cancer 2018 Jan 27;105(1):81-98. Epub 2017 Dec 27.

Cancer campus Grand-Paris, Gustave-Roussy cancer comprehensive center, département d'hématologie, 114, rue Édouard-Vaillant, 94805 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2017.11.008DOI Listing
January 2018

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

J Clin Oncol 2017 Dec 2;35(36):4027-4034. Epub 2017 Oct 2.

Tony S.K. Mok, The Chinese University of Hong Kong, Prince of Wales Hospital, Sha Tin, Hong Kong, Special Administrative Region, People's Republic of China; Yi-Long Wu and Jin-Ji Yang, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Jie Wang, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing; You Lu, Sichuan University, Sichuan; Xiaojin Shi, AstraZeneca, Shanghai, People's Republic of China; James Chih-Hsin Yang, The National Taiwan University Hospital and College of Medicine, Taipei, Taiwan, Republic of China; Sang-We Kim, University of Ulsan College of Medicine; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Seoul, South Korea; Kazuhiko Nakagawa, Kindai University; Shinji Atagi, Kinkichuo Chest Medical Center, Osaka, Japan; Santiago Ponce, Hospital Universitario 12 de Octubre, Madrid, Spain; Yuri Rukazenkov, AstraZeneca, Cambridge; Vincent Haddad, AstraZeneca, Royston, United Kingdom; Kenneth S. Thress, AstraZeneca, Waltham, MA; and Jean-Charles Soria, Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.9250DOI Listing
December 2017

In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?

Eur J Cancer 2017 12 7;87:65-74. Epub 2017 Nov 7.

Gustave Roussy, Département D'Innovation Thérapeutique et Essais Précoces, Villejuif, France; INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, F-94805, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.09.027DOI Listing
December 2017

Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3.

Oncotarget 2017 Dec 30;8(65):108786-108801. Epub 2017 Oct 30.

INSERM UMR1186, Integrative Tumor Immunology and Genetic Oncology, Gustave Roussy, Equipe Labellisée par La Ligue Contre Le Cancer, EPHE, Faculté de Médecine, Université Paris-Sud, Université Paris-Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22150DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752481PMC
December 2017

Reply to F. Tomao et al.

J Clin Oncol 2017 11 7;35(31):3633-3634. Epub 2017 Sep 7.

Patrick A. Ott, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; and Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.8681DOI Listing
November 2017

Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer.

Eur J Cancer 2017 11 13;85:155-157. Epub 2017 Sep 13.

Drug Development Department (DITEP), Gustave Roussy, and University Paris-Sud, Villejuif, France; INSERM U981, Gustave Roussy, University Paris XI, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.07.049DOI Listing
November 2017

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

Eur J Cancer 2017 10 18;84:202-211. Epub 2017 Aug 18.

Drug Development Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France; Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, 94800 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.07.033DOI Listing
October 2017

Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.

Lung Cancer 2017 10 29;112:10-15. Epub 2017 Jul 29.

Medical Oncology Department, Gustave Roussy, Villejuif, France; University Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.07.004DOI Listing
October 2017

LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.

Lung Cancer 2017 10 7;112:62-68. Epub 2017 Aug 7.

Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France; University Paris-Sud Kremlin Bicetre/Chatenay-Malabry, Le Kremlin-Bicêtre, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.08.002DOI Listing
October 2017

Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.

Eur J Cancer 2017 09 10;82:34-44. Epub 2017 Jul 10.

Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Service de Médecine Interne et Immunologie Clinique, F-94275 Le Kremlin-Bicêtre, France; INSERM, U1184, Immunology of Viral Infections and Autoimmune Diseases, F-94276 Le Kremlin-Bicêtre, France; Université Paris Sud, UMR 1184, F-94276 Le Kremlin-Bicêtre, France; CEA, DSV/iMETI, IDMIT, F-92265 Fontenay-aux-Roses, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.05.032DOI Listing
September 2017

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

Eur J Cancer 2017 09 22;83:185-193. Epub 2017 Jul 22.

Drug Development Department (DITEP), Gustave Roussy, 94805, Villejuif, France; Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Orsay, 91405, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.05.016DOI Listing
September 2017

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.

J Clin Oncol 2017 Aug 10;35(22):2535-2541. Epub 2017 May 10.

Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Michael J. Pishvaian, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Hope S. Rugo, University of California San Francisco, San Francisco, CA; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick; Marion Carrigan, Sanatan Saraf, and Mei Chen, Merck, Kenilworth, NJ; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Dominique Berton-Rigaud, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain; Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Kyaw L. Aung, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and Juanita Lopez, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.5952DOI Listing
August 2017

First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours.

Eur J Cancer 2017 08;81:142-150

Drug Development Department DITEP, Institut Gustave Roussy, 94805, Villejuif, France; Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Orsay, 91405, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.05.007DOI Listing
August 2017

Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.

J Clin Oncol 2017 Jun 28;35(18):2018-2027. Epub 2017 Apr 28.

Frances A. Shepherd and Ming-Sound Tsao, Princess Margaret Cancer Centre; University of Toronto, Toronto; Lesley Seymour, Queen's University, Kingston, Ontario, Canada; Benjamin Lacas, Gwénaël Le Teuff, Jean-Pierre Pignon, Thierry Le Chevalier, and Jean-Charles Soria, Institut Gustave-Roussy; Benjamin Lacas, Gwénaël Le Teuff, Jean-Pierre Pignon, Thierry Le Chevalier, and Jean-Charles Soria, University Paris XI, Paris; Pierre Hainaut, International Agency for Research on Cancer, Lyon; Jean-Yves Douillard, R Gauducheau, St Herblain; Elizabeth Brambilla, Inserm U823, Institut Albert Bonniot, Département de Pathologie CHU, Albert Michallon University Joseph Fourrier, Grenoble, France; Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA; Stephen Graziano, State University of New York Upstate Medical University, Syracuse, NY; Robert Kratzke, University of Minnesota Medical School, Minneapolis, MN; and Robert Pirker and Martin Filipits, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.2893DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075828PMC
June 2017

Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.

Lung Cancer 2017 06 27;108:72-74. Epub 2017 Feb 27.

Department of Cancer Medicine, Gustave Roussy, Villejuif, France; University Paris-Sud, Orsay, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.02.022DOI Listing
June 2017

Patient-reported tolerability of adverse events in phase 1 trials.

ESMO Open 2017 23;2(2):e000148. Epub 2017 Jun 23.

Drug Development department (DITEP), Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2016-000148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519806PMC
June 2017